Entrepreneur UK's London 100: Mamedica
Mamedica is a private clinic with a linked pharmacy specialising in cannabis-based prescriptions (from oil to cannabis flower)
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media.
Industry: Health and wellness
Mamedica is a private clinic with a linked pharmacy specialising in cannabis-based prescriptions (from oil to cannabis flower).
In the last year alone, they experienced a 2,000% revenue increase and a 675,000% growth since inception in their patient base, reflecting the urgent need for alternative treatments.
Founded by Jon Robson, and launched in 2022, Mamedica aims to deliver a quality of service which is currently lacking in the medical cannabis sector.
Mamedica puts patient safety, security, and satisfaction at the forefront of every activity, using only the most high-calibre consultants and support staff as part of their team.
Following a secure, private video consultation the medicines can be delivered directly to the patient's door via next-day delivery service.
All medications prescribed by Mamedica are produced and manufactured according to the pharmaceutical-grade EU-GMP (Good Manufacturing Practice), the most stringent in the world.
Patients can be assured that their medicines are not contaminated with pesticides or adulterants.
The medical cannabis market currently has north of 50,000 patients in the market - expected to rise to 300,000 plus by 2028.
The UK's medical cannabis market was valued at approximately £188m in 2023 and is projected to exceed £470m by 2027.
Around 60% of their patients seek treatment for psychological or neurological conditions, while 40% present with pain-related issues.
The most common conditions they support include anxiety (21%), depression (13%), chronic pain (12%), back and neck pain (10%), and ADHD (10%).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Europe Delays Stricter Banking Rules to Keep ‘Level Playing Field' With US Rivals
The European Union's executive arm is holding off on implementing new banking rules that could be tantamount to putting a potato sack around the legs of the region's lenders in the middle of a 100-yard dash against their US counterparts. The European Commission announced Thursday that the so-called Fundamental Review of the Trading Book, a boring technocratic name if there ever was one, will be delayed one year until 2027. It would place stricter rules on the region's investment-bank trading desks at a time when the US seems increasingly less inclined to impose similar regulations of its own. READ ALSO: Just How Much Data Does the Fed Need to Cut Rates? and Retail Investors Risk Ominous Opportunity Cost With Private Investments, Moody's Warns The new rules are part of the Basel III international banking reforms that were introduced in 2017 and designed in response to the 2008 financial crisis. Basel III is meant to create global standards for the way banks measure risk and enhance their ability to withstand shocks (a.k.a. prevent another systemic implosion worthy of an Oscar-winning Matt Damon-narrated documentary). Specifically, the Fundamental Review of the Trading Book will tighten how banks measure and hold reserves against their capital markets activities, zeroing in on investment banking. Investment banking, of course, is on an earnings tear on both sides of the Atlantic, with trading desks cashing in on volatile equities even as US tariff policy has curbed M&A activity. JPMorgan Chase and Morgan Stanley reported record revenue from their equity traders in the first quarter, while investment banking fees rose 12% at JPMorgan and 8% at Morgan Stanley. Deutsche Bank, Germany's largest lender, reported its highest quarterly pre-tax profit in 14 years in the first quarter, with its trading unit netting record revenues. Income at France's largest bank, BNP Paribas, slipped in its latest quarter, but the equities desk was a bright spot with a record result. Were the EU to implement the new rules now, however, the region's investment banks could look across the Atlantic and see a US administration less inclined to follow suit: Last year, the Federal Reserve softened its proposed Basel III rules after intense lobbying from the banking industry. That was even before the second Trump administration, which promised a deregulation-focused agenda, came into power. Last month, the Financial Times reported that US officials plan to roll back bank capital requirements in the next few months. In January, as Trump entered office, the UK put its own new capital rules on hold until 2027, with the Bank of England stating that it wanted to see what the US does first, in the interest of its own 'competitiveness and growth considerations.' The European Commission made a similar case Thursday, noting that 'concerns regarding the international level playing field and the impact on EU banks remain high.' Waiting Game: Banks are still waiting for a potential recovery in dealmaking, which would further boost investment fees, but that will require clarity from the Trump administration on trade policy. On May 29, Goldman Sachs President John Waldron told a conference that he saw a 'quite good' outlook for investment banking, adding that the 'pipeline is strong all over the world.' He did, however, flag volatility as an obstacle to deals. Earlier this week, Bank of America CEO Brian Brian Moynihan said at a conference that his bank expects investment banking fees to fall to $1.2 billion in the second quarter from $1.6 billion a year earlier. He said that's 'not where we want to be' but also flagged that there are 'great prospects.' This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
Bloomberg
2 hours ago
- Bloomberg
ECB Within Reach of 2% Inflation Goal, Lagarde Tells Xinhua
The European Central Bank is approaching its goal for consumer-price growth, President Christine Lagarde said, warning of uncertainty emanating from US tariffs. 'Our primary responsibility at the ECB is price stability, and this is clearly defined in our strategy,' Lagarde told the Xinhua News Agency. 'We are within reach of the 2% medium-term inflation target that we have defined as price stability. But we cannot have price stability if we do not have financial stability.'
Business Upturn
4 hours ago
- Business Upturn
Sun Pharma's Halol facility receives form 483 with 8 observations from US FDA
By Aman Shukla Published on June 14, 2025, 09:42 IST Sun Pharmaceutical Industries Limited, one of India's leading pharmaceutical companies, has announced the conclusion of a recent inspection by the United States Food and Drug Administration (US FDA) at its Halol manufacturing facility located in Gujarat, India. The inspection was conducted from June 2 to June 13, 2025, as part of the regulatory authority's routine evaluation of current Good Manufacturing Practices (GMP) compliance. At the end of the inspection, the US FDA issued a Form 483 to the company, outlining eight observations. In a regulatory filing, Sun Pharma stated: 'We hereby inform that the US FDA conducted a GMP inspection of our Halol facility from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483 with 8 observations.' A Form 483 is issued by the US FDA when its investigators observe any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related regulations. These observations are based on conditions found during routine inspections and are intended to prompt the company to take corrective actions. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
